<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622569</url>
  </required_header>
  <id_info>
    <org_study_id>OPN-FLU-NP-3101</org_study_id>
    <nct_id>NCT01622569</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety</brief_title>
  <official_title>A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optinose US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optinose US Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of intranasal administration
      of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose
      device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will
      be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4
      of the double-blind treatment phase measured by the 7 day average instantaneous AM diary
      symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities)
      over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale
      score measured by nasoendoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study
      designed to assess the efficacy and safety of intranasal administration of 3 doses of OPN-375
      (100, 200, and 400 µg bid) in subjects with bilateral nasal polyposis and nasal congestion.

      This study consisted of 3 phases. After signing informed consent, subjects who met
      eligibility criteria at Visit 1 (screening) entered the study.

        1. Pretreatment phase (single-blind, placebo, run-in): 7 to up to 14 days duration, to
           determine disease status eligibility and to ensure the subject was able to comply with
           study procedures prior to randomization and enrolment in the double-blind treatment
           phase.

        2. Double-blind treatment phase: 16 weeks duration with 6 scheduled visits starting with
           Visit 2, Day 1 (baseline) when eligible subjects were randomized by balance allocation
           to 1 of 4 treatment groups and ending at Visit 7 (Week 16).

        3. Open-label extension phase: 8 weeks duration with 1 scheduled visit (Visit 8 [Week 24]).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2013</start_date>
  <completion_date type="Actual">October 1, 2015</completion_date>
  <primary_completion_date type="Actual">August 6, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</measure>
    <time_frame>Baseline, Week 4 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Polyp Grade</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Congestion/Obstruction Scores (7-day Instantaneous Morning)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rhinorrhea Score (7-day Instantaneous Morning)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain or Pressure Score (7-day Instantaneous Morning)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyposmia Score (7-day Instantaneous Morning)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinonasal Outcome Test 22 (SNOT-22) Total Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
    <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOS Sleep-R Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinosinusitis Disability Index (RSDI) Total Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 - Mental Component</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
    <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 - Physical Component</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
    <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) Score</measure>
    <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
    <description>Subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase</time_frame>
    <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyp Grade of 0 in at Least One Nostril</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Polyp Surgery Eligilbilty</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Bilateral Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>OPN-375 100 μg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks
Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPN-375 200 μg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks
Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPN-375 400 μg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks
Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate</intervention_name>
    <description>Delivered via Optinose Exhalation Delivery System</description>
    <arm_group_label>OPN-375 100 μg BID</arm_group_label>
    <arm_group_label>OPN-375 200 μg BID</arm_group_label>
    <arm_group_label>OPN-375 400 μg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>OPN-375</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 years and older

          -  Women must

               -  be practicing an effective method of birth control (eg,prescription oral
                  contraceptives, contraceptive injections, contraceptive patch, intrauterine
                  device, double-barrier method [eg, condoms, diaphragm, or cervical cap with
                  spermicidal foam, cream, or gel], or male partner sterilization) before entry and
                  throughout the study, or

               -  be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or
                  tubal ligation at least 1 year before screening) or otherwise be incapable of
                  pregnancy, or

               -  be postmenopausal (spontaneous amenorrhea for at least 1 year).

          -  Women of child-bearing potential must have a negative serum beta-human chorionic
             gonadotropin (B-hCG) or urine pregnancy test (depending on local regulations) at the
             screening visit

          -  Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal
             cavities as determined by the Lildholdt scale score measured by nasoendoscopy at both
             screening and baseline visits

          -  Must have at least moderate symptoms of nasal congestion/obstruction as reported by
             the subject for the 7 day period preceding the screening visit

          -  At the baseline visit (Day 1), must have a morning score of at least 2 (moderate) on
             nasal congestion/obstruction recorded on the subject diary for at least 5 of the last
             7 days of the 7 to up to 14 day run-in period

          -  Must demonstrate an ability to correctly complete the daily diary during the run-in
             period to be eligible for randomization

          -  Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no
             emergency room visits, hospitalizations, or oral or parenteral steroid use) within the
             3 months before the screening visit. Inhaled corticosteroid use must be limited to
             stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at
             least 3 months before screening with plans to continue use throughout the study.

          -  Must be able to cease treatment with intranasal medications including, but not limited
             to, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium
             bromide, inhaled corticosteroids (except permitted doses listed above for comorbid
             asthma and COPD) at the screening visit

          -  Must be able to cease treatment with oral and nasal decongestants and antihistamines
             at the screening visit

          -  Must be able to use the OptiNose device correctly; all subjects will be required to
             demonstrate correct use of the placebo device at screening, Visit 1.

          -  Must be capable, in the opinion of the investigator, of providing informed consent to
             participate in the study. Subjects must sign an informed consent document indicating
             that they understand the purpose of and procedures required for the study and are
             willing to participate in the study.

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Have complete or near-complete obstruction of the nasal cavities

          -  Inability to achieve bilateral nasal airflow for any reason including nasal septum
             deviation

          -  Inability to have each nasal cavity examined for any reason including nasal septum
             deviation

          -  Nasal septum perforation

          -  Has had more than 1 episode of epistaxis with frank bleeding in the month before the
             screening visit

          -  Have evidence of significant baseline mucosal injury, ulceration or erosion (eg,
             exposed cartilage, perforation) on baseline nasal examination/nasal endoscopy

          -  History of more than 5 sinonasal surgeries for either nasal polyps or nasal/sinus
             inflammation (lifetime)

          -  History of sinus or nasal surgery within 6 months before the screening visit

          -  History of any surgical procedure that prevents the ability to accurately grade polyps

          -  Have symptoms of seasonal allergic rhinitis at screening or baseline and/or, based on
             time of year, would anticipate onset of symptoms within 4 weeks of randomization

          -  Current, ongoing rhinitis medicamentosa (rebound rhinitis)

          -  Have significant oral structural abnormalities, eg, a cleft palate

          -  Diagnosis of cystic fibrosis

          -  History of Churg-Strauss syndrome or dyskinetic ciliary syndromes

          -  Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within
             2 weeks before the screening visit. Potential subjects presenting with any of these
             infections may be rescreened 4 weeks after symptom resolution Note: Subjects who are
             taking prophylactic antibiotics will be allowed to enter the study as long as they
             intend to continue the antibiotics for the duration of the study.

          -  Planned sinonasal surgery during the period of the study

          -  Allergy, hypersensitivity, or contraindication to corticosteroids or steroids

          -  Allergy or hypersensitivity to any excipients in study drug

          -  Exposure to any glucocorticoid treatment with potential for systemic effects (eg,
             oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids)
             within 1 month before the screening visit; except as noted in inclusion criteria for
             subjects with comorbid asthma or COPD

          -  Have nasal candidiasis

          -  Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit.

          -  History or current diagnosis of any form of glaucoma or ocular hypertension (ie, &gt;21
             mmHg)

          -  History of intraocular pressure elevation on any form of steroid therapy

          -  History or current diagnosis of the presence (in either eye) of a cataract

          -  Any serious or unstable concurrent disease, psychiatric disorder, or any significant
             condition that, in the opinion of the investigator could confound the results of the
             study or could interfere with the subject's participation or compliance in the study

          -  A recent (within 1 year of the screening visit) clinically significant history of drug
             or alcohol use, abuse, or dependence that, in the opinion of the investigator could
             interfere with the subject's participation or compliance in the study

          -  Positive urine drug screen at screening visit for drugs of abuse, with the exception
             of prescribed medications for legitimate medical conditions

          -  Have participated in an investigational drug clinical trial within 30 days of the
             screening visit

          -  Employees of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SC Clinical Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kern Allergy and Medical Research, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central California Clinical Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Specialists Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Allergy &amp; Asthma Medical Group, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choc PSF, AMC, Division of AA &amp; I</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Allergy and Asthma Palmdale</name>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates, Inc.</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Associates, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado ENT &amp; Allergy</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers, P.C.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Asthma, Allergy &amp; Immunology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NU Feinberg School of Medicine Depart. of Otolaryngology-Head &amp; Neck Surgery</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago ENT</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates, Inc</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, P.C.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Group of Montana, PLLC</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Ear, Nose and Throat, LLC</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthma &amp; Urticaria Centers of Charleston, P.A.</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ear Nose and Throat Associates of Texas</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENTTEX</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EVMS Depart. Of Otolaryngology</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Sinus Center, S.C.</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Allergy Research Corporation</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hôtel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jaime Del Carpio</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <results_first_submitted>October 17, 2017</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <disposition_first_submitted>July 25, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2016</disposition_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>100 μg OPN-375</title>
          <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>200 μg OPN-375</title>
          <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>400 μg EDS-FLU</title>
          <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Phase (Wks 1-16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Phase (Wks 17-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>OPN-375 100 μg BID</title>
          <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>OPN-375 200 μg BID</title>
          <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>OPN-375 400 μg BID</title>
          <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="13.0"/>
                    <measurement group_id="B2" value="44.9" spread="12.7"/>
                    <measurement group_id="B3" value="46.4" spread="12.7"/>
                    <measurement group_id="B4" value="43.9" spread="12.6"/>
                    <measurement group_id="B5" value="45.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Polyp Grading Score (sum of scores from both nasal cavities)</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.
Included patients with nasal polyps at baseline</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B2" value="3.6" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B3" value="3.9" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B4" value="3.7" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B5" value="3.75" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of intranasal corticosteroid (ICS) treatment for polyps in past 10 years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous sinus surgery for polyp removal or sinus surgery</title>
          <description>Patients may have had both sinus surgery and polypectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous polyp removal surgery via polypectomy only</title>
          <description>Patients may have had both sinus surgery and polypectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Congestion/Obstruction Score (7-Day Instantaneous Morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild - symptoms clearly present, but minimal awareness, and easily tolerated
Moderate - definite awareness of symptoms that is bothersome but tolerable
Severe - symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.31" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.22" lower_limit="0.8" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.24" lower_limit="1.6" upper_limit="3.0"/>
                    <measurement group_id="B4" value="2.29" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="B5" value="2.27" lower_limit="0.8" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rhinorrhea Score (7-day instantaneous morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild - symptoms clearly present, but minimal awareness, and easily tolerated
Moderate - definite awareness of symptoms that is bothersome but tolerable
Severe - symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.81" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="1.67" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="1.75" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B4" value="1.83" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="1.76" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Facial Pain or Pressure Score (7-day instantaneous morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild - Symptoms clearly present, but minimal awareness, and easily tolerated
Moderate - Definite awareness of symptoms that is bothersome but tolerable
Severe - Symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.65" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="1.53" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="1.48" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B4" value="1.62" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="1.57" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyposomia Score (7-day instantaneous morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild - Symptoms clearly present, but minimal awareness, and easily tolerated
Moderate - Definite awareness of symptoms that is bothersome but tolerable
Severe - Symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, an who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.42" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.31" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.49" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B4" value="2.44" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="2.41" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as can be</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="77"/>
                    <count group_id="B5" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" lower_limit="14" upper_limit="95"/>
                    <measurement group_id="B2" value="46.1" lower_limit="14" upper_limit="95"/>
                    <measurement group_id="B3" value="51.8" lower_limit="0" upper_limit="108"/>
                    <measurement group_id="B4" value="52.4" lower_limit="6" upper_limit="103"/>
                    <measurement group_id="B5" value="51" lower_limit="0" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Study Sleep Scale Revised (MOS Sleep-R)</title>
          <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" lower_limit="5.6" upper_limit="97.2"/>
                    <measurement group_id="B2" value="37.8" lower_limit="2.8" upper_limit="77.8"/>
                    <measurement group_id="B3" value="46.6" lower_limit="11.1" upper_limit="91.7"/>
                    <measurement group_id="B4" value="43.7" lower_limit="11.1" upper_limit="88.9"/>
                    <measurement group_id="B5" value="42.71" lower_limit="2.8" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
          <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="79"/>
                    <count group_id="B4" value="78"/>
                    <count group_id="B5" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" lower_limit="2" upper_limit="120"/>
                    <measurement group_id="B2" value="39.8" lower_limit="2" upper_limit="96"/>
                    <measurement group_id="B3" value="45.2" lower_limit="3" upper_limit="91"/>
                    <measurement group_id="B4" value="45.4" lower_limit="5" upper_limit="117"/>
                    <measurement group_id="B5" value="44.69" lower_limit="2" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form (36) Health Survey Version 2 (SF-36v2) - Mental Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="79"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" lower_limit="23.66" upper_limit="63.99"/>
                    <measurement group_id="B2" value="49.0" lower_limit="22.18" upper_limit="63.08"/>
                    <measurement group_id="B3" value="46.0" lower_limit="18.06" upper_limit="58.7"/>
                    <measurement group_id="B4" value="47.8" lower_limit="15.26" upper_limit="62.61"/>
                    <measurement group_id="B5" value="47.6" lower_limit="15.26" upper_limit="63.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form (36) Health Survey Version 2 (SF-36v2) - Physical Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="79"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="27.75" upper_limit="57.53"/>
                    <measurement group_id="B2" value="44.7" lower_limit="28.01" upper_limit="60.58"/>
                    <measurement group_id="B3" value="43.9" lower_limit="28.36" upper_limit="60.91"/>
                    <measurement group_id="B4" value="43.9" lower_limit="22.58" upper_limit="59.26"/>
                    <measurement group_id="B5" value="44" lower_limit="22.58" upper_limit="60.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Nasal Inspiratory Flow (PNIF)</title>
          <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="79"/>
                    <count group_id="B4" value="79"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.1" lower_limit="30" upper_limit="350"/>
                    <measurement group_id="B2" value="111.6" lower_limit="0" upper_limit="360"/>
                    <measurement group_id="B3" value="97.1" lower_limit="30" upper_limit="350"/>
                    <measurement group_id="B4" value="103.2" lower_limit="25" upper_limit="340"/>
                    <measurement group_id="B5" value="104.3" lower_limit="0" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Polyp Surgery Eligibility</title>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="82"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="78"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase</description>
        <time_frame>Baseline, Week 4 of the double-blind treatment phase</time_frame>
        <population>Missing data were imputed using the multiple imputation method in the primary analyses for the co-primary efficacy variables. For other efficacy analyses, missing or invalid values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase</description>
          <population>Missing data were imputed using the multiple imputation method in the primary analyses for the co-primary efficacy variables. For other efficacy analyses, missing or invalid values were not imputed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.08"/>
                    <measurement group_id="O2" value="-0.53" spread="0.08"/>
                    <measurement group_id="O3" value="-0.56" spread="0.08"/>
                    <measurement group_id="O4" value="-0.67" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Polyp Grade</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Polyp Grade</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.14"/>
                    <measurement group_id="O2" value="-1.04" spread="0.14"/>
                    <measurement group_id="O3" value="-1.14" spread="0.14"/>
                    <measurement group_id="O4" value="-1.14" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Congestion/Obstruction Scores (7-day Instantaneous Morning)</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg Twice Daily</title>
            <description>100 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg Twice Daily</title>
            <description>200 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg Twice Daily</title>
            <description>OPN-375 400 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Congestion/Obstruction Scores (7-day Instantaneous Morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.11"/>
                    <measurement group_id="O2" value="-0.93" spread="0.10"/>
                    <measurement group_id="O3" value="-0.99" spread="0.10"/>
                    <measurement group_id="O4" value="-1.07" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rhinorrhea Score (7-day Instantaneous Morning)</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinorrhea Score (7-day Instantaneous Morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.10"/>
                    <measurement group_id="O2" value="-0.80" spread="0.10"/>
                    <measurement group_id="O3" value="-0.89" spread="0.10"/>
                    <measurement group_id="O4" value="-0.92" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain or Pressure Score (7-day Instantaneous Morning)</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain or Pressure Score (7-day Instantaneous Morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.11"/>
                    <measurement group_id="O2" value="-0.65" spread="0.10"/>
                    <measurement group_id="O3" value="-0.72" spread="0.10"/>
                    <measurement group_id="O4" value="-0.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyposmia Score (7-day Instantaneous Morning)</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hyposmia Score (7-day Instantaneous Morning)</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.12"/>
                    <measurement group_id="O2" value="-0.45" spread="0.11"/>
                    <measurement group_id="O3" value="-0.53" spread="0.11"/>
                    <measurement group_id="O4" value="-0.60" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
        <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.96" spread="2.07"/>
                    <measurement group_id="O2" value="-18.32" spread="2.05"/>
                    <measurement group_id="O3" value="-19.56" spread="2.04"/>
                    <measurement group_id="O4" value="-19.80" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 24 (all pts on 400 μg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.78" spread="2.10"/>
                    <measurement group_id="O2" value="-21.20" spread="2.07"/>
                    <measurement group_id="O3" value="-23.28" spread="2.08"/>
                    <measurement group_id="O4" value="-21.72" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MOS Sleep-R Score</title>
        <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MOS Sleep-R Score</title>
          <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.53" spread="1.61"/>
                    <measurement group_id="O2" value="-10.96" spread="1.59"/>
                    <measurement group_id="O3" value="-14.24" spread="1.59"/>
                    <measurement group_id="O4" value="-10.66" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
        <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
          <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.71" spread="2.07"/>
                    <measurement group_id="O2" value="-17.08" spread="1.99"/>
                    <measurement group_id="O3" value="-16.44" spread="2.02"/>
                    <measurement group_id="O4" value="-16.37" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36v2 - Mental Component</title>
        <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36v2 - Mental Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.87"/>
                    <measurement group_id="O2" value="3.19" spread="0.84"/>
                    <measurement group_id="O3" value="4.03" spread="0.85"/>
                    <measurement group_id="O4" value="1.83" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="0.83"/>
                    <measurement group_id="O2" value="3.37" spread="0.80"/>
                    <measurement group_id="O3" value="5.82" spread="0.84"/>
                    <measurement group_id="O4" value="3.61" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36v2 - Physical Component</title>
        <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36v2 - Physical Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.76"/>
                    <measurement group_id="O2" value="4.12" spread="0.74"/>
                    <measurement group_id="O3" value="5.19" spread="0.74"/>
                    <measurement group_id="O4" value="3.58" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" spread="0.78"/>
                    <measurement group_id="O2" value="6.55" spread="0.75"/>
                    <measurement group_id="O3" value="7.18" spread="0.78"/>
                    <measurement group_id="O4" value="4.90" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGIC) Score</title>
        <description>Subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
        <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGIC) Score</title>
          <description>Subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Nasal Inspiratory Flow (PNIF)</title>
        <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg BID</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg BID</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg BID</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Nasal Inspiratory Flow (PNIF)</title>
          <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.26" spread="6.15"/>
                    <measurement group_id="O2" value="36.57" spread="6.06"/>
                    <measurement group_id="O3" value="35.94" spread="6.08"/>
                    <measurement group_id="O4" value="35.43" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.92" spread="6.31"/>
                    <measurement group_id="O2" value="41.61" spread="6.21"/>
                    <measurement group_id="O3" value="44.70" spread="6.27"/>
                    <measurement group_id="O4" value="35.64" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Polyp Grade of 0 in at Least One Nostril</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 μg Twice Daily</title>
            <description>100 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 μg Twice Daily</title>
            <description>200 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 μg Twice Daily</title>
            <description>400 μg Twice Daily x 16 weeks, then OPN-375 400 μg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Polyp Grade of 0 in at Least One Nostril</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on 400 μg OPN-375 BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Polyp Surgery Eligilbilty</title>
        <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>100 μg OPN-375</title>
            <description>OPN-375 100 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>200 μg OPN-375</title>
            <description>OPN-375 200 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>400 μg EDS-FLU</title>
            <description>OPN-375 400 μg BID x 16 weeks, then OPN-375 (open-label) 400 μg BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Polyp Surgery Eligilbilty</title>
          <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Analysis Set (SAS) included all ITT subjects who received at least 1 dose of study drug. The SAS was used for the analysis of safety. The treatment group classification in the SAS was according to the treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Double-Blind Phase)</title>
          <description>100 μg BID or 200 μg BID or 400 μg Matching Placebo BID x 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>OPN-375 100 μg BID (Double-Blind Phase)</title>
          <description>OPN-375 100 μg BID x 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>OPN-375 200 μg BID (Double-Blind Phase)</title>
          <description>OPN-375 200 μg BID x 16 weeks</description>
        </group>
        <group group_id="E4">
          <title>OPN-375 400 μg BID (Double-Blind Phase)</title>
          <description>OPN-375 400 μg BID x 16 weeks</description>
        </group>
        <group group_id="E5">
          <title>OPN-375 400 μg (Open-Label Phase)</title>
          <description>OPN-375 400 μg BID x 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract Nuclear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis (Spontaneously Reported by Subject)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nasal Mucosal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nasal Septal Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Nasal Septum Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Epistaxis (Found on Nasoendoscopy)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure agreement is described in CTA between sponsor and PI</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Global Clinical Operations &amp; Outsourcing</name_or_title>
      <organization>OptiNose</organization>
      <phone>267-364-3508</phone>
      <email>jennifer.carothers@optinose.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

